PE/Cyanine7 anti-human CD209 (DC-SIGN) Antibody
- 产品名称：
- PE/Cyanine7 anti-human CD209 (DC-SIGN) Antibody
- 产品类别：
- 抗体
- 产品编号：
- 330113
- 产品应用：
- 330113
[价格]
| 规格 |
价格 |
库存 |
| 25tests |
￥ 1836 |
1 |
- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- Extracellular domain of human DC-SIGN
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
- Preparation
- The antibody was purified by affinity chromatography and conjugated with PE/Cyanine7 under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
- Excitation Laser
- Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
- Application Notes
Additional reported applications (for the relevant formats) include: immunohistochemistry on frozen tissue sections1?and spatial biology (IBEX)2,3.
- Additional Product Notes
- BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
- Application References
(PubMed link indicates BioLegend citation) -
- Granelli-Piperno A, et al. 2005. J Immunol. 175:4265. (IHC-F)
- Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
- Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed
- Product Citations
-
- Ogishi M, et al. 2022. J Exp Med. 219:. PubMed
- Forbester JL, et al. 2020. J Virol. 94:. PubMed
- Guo J, et al. 2019. Cancer Immunol Res. 1.349305556. PubMed
- Mulder K, et al. 2021. Immunity. 54(8):1883-1900.e5. PubMed
- Parker R, et al. 2021. Cell Reports. 35(8):109179. PubMed
- RRID
- AB_10719952 (BioLegend Cat. No. 330113) AB_10719953 (BioLegend Cat. No. 330114)
